BHC Stock Recent News

BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.

Bausch Health Companies Inc. (NYSE:BHC ) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Garen Sarafian - VP & Head of Investor Relations Jean-Jacques Charhon - Executive VP & CFO Thomas J. Appio - CEO & Director Conference Call Participants Douglas Miehm - RBC Capital Markets, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Operator Welcome to the Bausch Health First Quarter 2025 Earnings Call.

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bausch Health (BHC) came out with quarterly earnings of $0.9 per share, missing the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.89 per share a year ago.

Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health Companies of $148 million and GAAP Net Income of $128 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP)1 of $842 million, up 6% on a Reported basis over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB SECOND QUARTER 2025 RESULTS Delivered ninth consecutive quarter of year-over-year Revenue and Adjusted EBITDA (non-GAAP)1 growth, with 5% both Reported and Organic (non-GAAP)1 Revenue growth, and 10% Adjusted EBITDA (non-GAAP)1 growth Announced upcoming repayment of approximately $900 million dollars of debt using cash on hand after quarter-end Entered into an agreement to acquire DURECT Corporation in July, which if all closing conditions are satisfied and the acquisition closes, will enable Bausch Health to use its hepatology expertise to seek to g

Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness. “Since launching in 2018, LUMIFY has been the No. 1 doctor-recommended redn.

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitis Proposed acquisition strengthens Bausch Health's commitment to hepatology and patients suffering with liver disease complications globally LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / July 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) today announced a definitive agreement under which Bausch Health will indirectly acquire DURECT Corporation, including a novel therapeutic molecule, larsucosterol, which can harness the power of epigenetic modulation. Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for the treatment of alcoholic hepatitis (AH) in Phase 2 trials.

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitis Proposed acquisition strengthens Bausch Health's commitment to hepatology and patients suffering with liver disease complications globally LAVAL, QC and CUPERTINO, Calif. , July 29, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ: DRRX) today announced a definitive agreement under which Bausch Health will indirectly acquire DURECT Corporation, including a novel therapeutic molecule, larsucosterol, which can harness the power of epigenetic modulation.

LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., has issued an irrevocable notice of redemption pursuant to which it will redeem approximately $602 million of aggregate principal amount of its outstanding 9.25% Senior Notes due 2026, CUSIP Nos. 91911XAV6 and U9098VAN2 (the "Notes"), using cash on hand.